A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
Study Summary
The goal of this study is to further characterise the potential long-term safety risks of lonapegsomatropin in patients treated with lonapegsomatropin under real-world conditions in the post-marketing setting.
Lead SponsorAscendis Pharma Endocrinology Division A/S
Data Retrieved2026-04-11 02:54:40.919380+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.